Seidu, Samuel
Funding for this research was provided by:
Abbott Fund
Article History
Received: 25 July 2023
Accepted: 13 December 2023
First Online: 13 January 2024
Declarations
:
: Samuel Seidu reports personal fees from NAPP, Amgen, Astra Zeneca, Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche, Abbot, Boehringer Ingelheim and Sanofi-Aventis, and grants from AstraZeneca, Sanofi-Aventis, Servier and Janssen, outside the submitted work.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.